HealthMyne
HealthMyne provides AI-powered quantitative imaging decision support for oncology workflows, serving radiologists, oncologists, and cancer centers with consistent lesion measurement, radiomics, and multidisciplinary tumor board reporting through its QIDS platform.
- Company typePrivate
- Founded2012
- HeadquartersMadison, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What HealthMyne does
HealthMyne is a Madison, Wisconsin-based healthcare technology company founded in 2012 that develops the QIDS (Quantitative Imaging Decision Support) platform, an enterprise SaaS solution for oncology workflow management. The platform addresses inconsistent lesion measurement in radiology (where inter/intra-reader variability can reach 37%) by applying AI/ML-driven segmentation and radiomics to extract 600+ quantitative metrics per lesion from CT, MRI, and PET imaging studies. The core engine, branded Rapid Precise Metrics (RPM), propagates measurements forward across follow-up studies and feeds seven modular add-ons: Cancer Screening, Tumor Conference, Therapy Response, Incidental Findings, Thoracic, PatientCare Timeline, and Reports. QIDS operates at both the point-of-read (radiologist workflow, with native Nuance PowerScribe and M*Modal dictation integration) and the point-of-care (multidisciplinary clinical decision-making).
HealthMyne firmographics
Firmographics- Name
- HealthMyne
- Legal name
- HealthMyne
- Website
- https://healthmyne.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HealthMyne provides AI-powered quantitative imaging decision support for oncology workflows, serving radiologists, oncologists, and cancer centers with consistent lesion measurement, radiomics, and multidisciplinary tumor board reporting through its QIDS platform.
- Ownership category
- akta.pro rank
HealthMyne industry classification
Industry- Product category
- Medical Imaging Analytics
- NAICS
- Diagnostic Imaging Centers (621512), Scientific Research and Development Services (5417)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Medical Imaging AI (HDAAAEAH), Radiation Dose Management & Analytics (HLACALAH), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)
Keywords
Where HealthMyne is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
HealthMyne business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Platform Licensing/Subscription: B2B SaaS platform licensing model targeting healthcare organizations, hospitals, and cancer centers. The platform appears to be sold as an enterprise solution with modules for different clinical workflows (Cancer Screening, Therapy Response, Tumor Conference, Incidental Findings, Thoracic).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise quote-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
HealthMyne product offering
Product offeringCore offering
HealthMyne provides a Quantitative Imaging Decision Support (QIDS) platform that integrates AI/ML-powered medical image analysis with EMR/PACS data to deliver consistent lesion measurements, over 600 quantitative radiomic metrics per lesion, and clinical decision support for oncology workflows. The platform operates at both the radiologist's point-of-read and the clinician's point-of-care, with modules covering cancer screening, tumor conferences, therapy response, incidental findings, thoracic care, and longitudinal patient timelines.
Product overview
HealthMyne offers the QIDS (Quantitative Imaging Decision Support) Platform, an integrated SaaS platform that enables better patient management decisions for Oncology. The platform consists of a core engine (Rapid Precise Metrics/RPM) that provides consistent lesion identification, measurement, and tracking across imaging studies, combined with seven specialized modules: Cancer Screening Module for tracking at-risk patients, Tumor Conference Module for streamlining multidisciplinary tumor boards, Therapy Response Module for tracking treatment outcomes, Incidental Findings Module for follow-up tracking, Thoracic Module for lung condition assessment, PatientCare Timeline for longitudinal patient data display, and Reports Module for quantitative reporting including the Quantitative Tumor Burden Report (QTBR). The platform operates at both the Point-of-Read (where radiologists perform measurements) and Point-of-Care (where care teams make decisions), with features including dictation integration, radiomics extraction, and advanced imaging overlays (PET/CT, MRI, radiotherapy dose).
Differentiator
Problem solved
Functional benefit
Brands
- QIDS: Quantitative Imaging Decision Support platform for oncology workflow management
- Rapid Precise Metrics (RPM)
- PatientCare Timeline
- Quantitative Tumor Burden Report (QTBR)
Products and services
- QIDS Platform Quantitative Imaging Decision Support (QIDS) platform that enables better patient management decisions for Oncology by integrating quantitative imaging data with clinical information from EMR and other systems. Designed for radiologists (point-of-read) and multidisciplinary care teams (point-of-care).
- Cancer Screening Module Module for tracking, communicating, and reporting on patients at risk for developing cancer, automating tasks such as tracking, communicating and reporting in cancer screening workflows including lung screening programs.
- Tumor Conference Module Module that streamlines processes for Tumor Conference preparation and management and improves communication among multidisciplinary care teams during tumor boards.
- Therapy Response Module Module for tracking patients as they progress through treatment and more accurately assessing outcomes using quantitative imaging metrics including volumetric changes.
- Incidental Findings Module Module for efficient tracking of incidental findings, ensuring patients and clinicians are kept informed with automated follow-up guidelines to address the historical 70%+ follow-up failure rate.
- Thoracic Module Module providing quantitative metrics and visualizations that assist clinicians in diagnosis and care of lung conditions, including emphysema assessment with automated segmentation of CT images.
- PatientCare Timeline Intuitive and interactive longitudinal display of EMR and other clinical data that integrates EMR, PACS, Radiotherapy, and other clinical systems data into a patient-centric view to enable multidisciplinary collaboration.
- Reports Module Module that presents quantitative imaging information in a clean logical manner including the Quantitative Tumor Burden Report (QTBR) for consolidated tumor burden assessment across studies.
Quantifiable outcome
- 93% consistency in lesion measurement vs 85% for traditional caliper methods (validated using LIDC dataset)
- +4 more outcomes
Companies that use HealthMyne
Customer profileSegments5 records
Ideal customer profiles1 record
HealthMyne technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature7 records
HealthMyne partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
HealthMyne competitors and assessment
Company assessmentMarket position
Strengths5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
HealthMyne social profiles
Digital presenceHealthMyne financial estimates
Financial estimateRevenue estimate
Valuation estimate
HealthMyne leadership team
Management profileNumber of profiles
Profiles1 record
HealthMyne funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HealthMyne M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HealthMyne
What does HealthMyne do?
HealthMyne provides a Quantitative Imaging Decision Support (QIDS) platform that integrates AI/ML-powered medical image analysis with EMR/PACS data to deliver consistent lesion measurements, over 600 quantitative radiomic metrics per lesion, and clinical decision support for oncology workflows. The platform operates at both the radiologist's point-of-read and the clinician's point-of-care, with modules covering cancer screening, tumor conferences, therapy response, incidental findings, thoracic care, and longitudinal patient timelines.
Is HealthMyne a public or private company?
HealthMyne is a private company. It is classified as venture growth investor backed and is currently operating.
When was HealthMyne founded?
HealthMyne was founded in 2012. It employs 11 to 50 people.
Where is HealthMyne based?
HealthMyne is headquartered in Madison, United States, in the North America region.
How does HealthMyne make money?
One revenue line is on record: platform Licensing/Subscription.
Does HealthMyne have an API?
No public API is recorded for HealthMyne.
What industry is HealthMyne in?
HealthMyne's product category is Medical Imaging Analytics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 621512 and its SIC code is 8000.